<HashMap><database>biostudies-literature</database><scores/><additional><submitter>Goel RR</submitter><funding>NIAID NIH HHS</funding><funding>NHLBI NIH HHS</funding><funding>NCI NIH HHS</funding><funding>NIAMS NIH HHS</funding><pagination>abm0829</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC9284784</full_dataset_link><repository>biostudies-literature</repository><omics_type>Unknown</omics_type><volume>374(6572)</volume><pubmed_abstract>The durability of immune memory after severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) messenger RNA (mRNA) vaccination remains unclear. In this study, we longitudinally profiled vaccine responses in SARS-CoV-2–naïve and –recovered individuals for 6 months after vaccination. Antibodies declined from peak levels but remained detectable in most subjects at 6 months. By contrast, mRNA vaccines generated functional memory B cells that increased from 3 to 6 months postvaccination, with the majority of these cells cross-binding the Alpha, Beta, and Delta variants. mRNA vaccination further induced antigen-specific CD4&lt;sup>+&lt;/sup> and CD8&lt;sup>+&lt;/sup> T cells, and early CD4&lt;sup>+&lt;/sup> T cell responses correlated with long-term humoral immunity. Recall responses to vaccination in indivi</pubmed_abstract><journal>Science (New York, N.Y.)</journal><pubmed_title>mRNA vaccines induce durable immune memory to SARS-CoV-2 and variants of concern.</pubmed_title><pmcid>PMC9284784</pmcid><funding_grant_id>R38 HL143613</funding_grant_id><funding_grant_id>R01 AI155577</funding_grant_id><funding_grant_id>R01 AI105343</funding_grant_id><funding_grant_id>R01 AI152236</funding_grant_id><funding_grant_id>T32 AI070077</funding_grant_id><funding_grant_id>P01 AI108545</funding_grant_id><funding_grant_id>T32 AI055400</funding_grant_id><funding_grant_id>U19 AI082630</funding_grant_id><funding_grant_id>T32 AR076951</funding_grant_id><funding_grant_id>R21 AI142638</funding_grant_id><funding_grant_id>U19 AI149680</funding_grant_id><funding_grant_id>T32 CA009140</funding_grant_id><funding_grant_id>P30 AI045008</funding_grant_id><pubmed_authors>Drapeau EM</pubmed_authors><pubmed_authors>Sette A</pubmed_authors><pubmed_authors>Herring S</pubmed_authors><pubmed_authors>Vella LA</pubmed_authors><pubmed_authors>Hamilton JT</pubmed_authors><pubmed_authors>Korte S</pubmed_authors><pubmed_authors>Kuthuru O</pubmed_authors><pubmed_authors>Meng W</pubmed_authors><pubmed_authors>Awofolaju M</pubmed_authors><pubmed_authors>Long S</pubmed_authors><pubmed_authors>Davenport MP</pubmed_authors><pubmed_authors>Hensley SE</pubmed_authors><pubmed_authors>Goel RR</pubmed_authors><pubmed_authors>Greenplate AR</pubmed_authors><pubmed_authors>Painter MM</pubmed_authors><pubmed_authors>Wherry EJ</pubmed_authors><pubmed_authors>Gouma S</pubmed_authors><pubmed_authors>Frank I</pubmed_authors><pubmed_authors>Luning Prak ET</pubmed_authors><pubmed_authors>UPenn COVID Processing Unit‡</pubmed_authors><pubmed_authors>Bates P</pubmed_authors><pubmed_authors>Giles JR</pubmed_authors><pubmed_authors>Dysinger S</pubmed_authors><pubmed_authors>Baxter AE</pubmed_authors><pubmed_authors>Oldridge DA</pubmed_authors><pubmed_authors>D'Andrea K</pubmed_authors><pubmed_authors>Hicks P</pubmed_authors><pubmed_authors>Sharma H</pubmed_authors><pubmed_authors>Apostolidis SA</pubmed_authors><pubmed_authors>Mathew D</pubmed_authors><pubmed_authors>Adamski S</pubmed_authors><pubmed_authors>Pattekar A</pubmed_authors><pubmed_authors>Grifoni A</pubmed_authors><pubmed_authors>Reynaldi A</pubmed_authors><pubmed_authors>McLaughlin M</pubmed_authors><pubmed_authors>Rosenfeld AM</pubmed_authors><pubmed_authors>Dougherty J</pubmed_authors><pubmed_authors>Weiskopf D</pubmed_authors><pubmed_authors>Kuri-Cervantes L</pubmed_authors><pubmed_authors>Lundgreen KA</pubmed_authors><pubmed_authors>Weirick ME</pubmed_authors><pubmed_authors>Williams JC</pubmed_authors><pubmed_authors>Hicks A</pubmed_authors><pubmed_authors>Betts MR</pubmed_authors><pubmed_authors>Khoury DS</pubmed_authors><pubmed_authors>McAllister CM</pubmed_authors><pubmed_authors>Tanenbaum N</pubmed_authors></additional><is_claimable>false</is_claimable><name>mRNA vaccines induce durable immune memory to SARS-CoV-2 and variants of concern.</name><description>The durability of immune memory after severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) messenger RNA (mRNA) vaccination remains unclear. In this study, we longitudinally profiled vaccine responses in SARS-CoV-2–naïve and –recovered individuals for 6 months after vaccination. Antibodies declined from peak levels but remained detectable in most subjects at 6 months. By contrast, mRNA vaccines generated functional memory B cells that increased from 3 to 6 months postvaccination, with the majority of these cells cross-binding the Alpha, Beta, and Delta variants. mRNA vaccination further induced antigen-specific CD4&lt;sup>+&lt;/sup> and CD8&lt;sup>+&lt;/sup> T cells, and early CD4&lt;sup>+&lt;/sup> T cell responses correlated with long-term humoral immunity. Recall responses to vaccination in indivi</description><dates><release>2021-01-01T00:00:00Z</release><publication>2021 Dec</publication><modification>2026-05-09T14:27:13.992Z</modification><creation>2025-04-04T03:20:21.209Z</creation></dates><accession>S-EPMC9284784</accession><cross_references><pubmed>34648302</pubmed><doi>10.1126/science.abm0829</doi></cross_references></HashMap>